Carotid intima-media thickness

From Citizendium
Revision as of 14:44, 22 January 2009 by imported>Robert Badgett (New page: In medicine and cardiovascular disease, the '''carotid intima-media thickness''' (CIMT) is a surrogate outcome measure used in randomized controlled trials of the treatment of ...)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

In medicine and cardiovascular disease, the carotid intima-media thickness (CIMT) is a surrogate outcome measure used in randomized controlled trials of the treatment of atherosclerosis.[1] It is suggested that "an annual increase of 0.03 mm in intima–media thickness was associated with a tripling of the rate of coronary events."[1]

A meta-analysis concludes "the modest relation between CIMT and coronary atherosclerosis most likely reflects variability in atherosclerosis development between the vascular beds rather than limitations of CIMT measurements."[2]

References

  1. 1.0 1.1 Brown BG, Taylor AJ (April 2008). "Does ENHANCE diminish confidence in lowering LDL or in ezetimibe?". N. Engl. J. Med. 358 (14): 1504–7. DOI:10.1056/NEJMe0801608. PMID 18376002. Research Blogging.
  2. Bots ML, Baldassarre D, Simon A, et al (February 2007). "Carotid intima-media thickness and coronary atherosclerosis: weak or strong relations?". Eur. Heart J. 28 (4): 398–406. DOI:10.1093/eurheartj/ehl482. PMID 17277033. Research Blogging.